Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

Panelists discuss how strategic sequencing decisions in frontline CLL therapy, informed by new evidence from the Rhodes et al. ASH 2024 study, have downstream implications for managing treatment ...

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard therapy for patients with chronic lymphocytic leukemia (CLL) who have ...

The US Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) for ofatumumab (Arzerra, Genmab/Novartis) for its use in combination with fludarabine and ...

SAN DIEGO -- Single-agent epcoritamab (Epkinly) achieved encouraging response rates in patients with heavily-pretreated chronic lymphocytic leukemia (CLL), according to early results from a phase I ...

BGB-16673 is an investigational oral BTK-targeted chimeric degradation activation compound. The Food and Drug Administration (FDA) has granted Fast Track designation to BGB-16673 for the treatment of ...

Despite major advances in targeted therapy, chronic lymphocytic leukemia (CLL) remains largely incurable. Resistance to ...

At a median duration of follow-up of 6.6 months, treatment with pirtobrutinib reduced the risk of progression or death by 42%. The Food and Drug Administration (FDA) has approved Jaypirca ® ...

Jaypirca showed higher ORR than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL patients, with 87% vs. 78.5% overall. Progression-free survival trends favored Jaypirca, particularly ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39 percent in heavily pretreated patients with relapsed or ...

LOS ANGELES--(BUSINESS WIRE)--City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United States, whose Los Angeles comprehensive cancer center is ...